Can a new drug shrink dangerous plaque in the heart?
NCT ID NCT07447648
Summary
This study aims to see if adding the drug Evinacumab to standard treatment can better control dangerous plaque buildup in the arteries of people with a rare, severe form of genetic high cholesterol (HoFH). Researchers will compare two groups of about 52 patients: one receiving Evinacumab and one receiving standard care. They will use heart scans taken during routine doctor visits to measure changes in plaque volume over 18-24 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.